Can­cer drug ri­vals at Loxo and Blue­print go toe-to-toe once again, and one an­a­lyst scores a (pos­si­ble) win on points

Who’s ready to start the week com­par­ing da­ta on two ri­val can­cer drugs from stud­ies fea­tur­ing dif­fer­ent tri­al de­signs?

OK, I’ll do it any­way.

Loxo On­col­o­gy $LOXO and Blue­print Med­i­cines $BPMC have been duk­ing it out with their ear­ly-stage stud­ies on their RET in­hibitors, and they were both back at it with up­dates for mu­tant medullary thy­roid can­cer at the Amer­i­can Thy­roid As­so­ci­a­tion meet­ing over the week­end.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.